Michaeli, D. T. & Michaeli, T. Launch and post-launch prices of injectable cancer drugs in the US: clinical benefit, innovation, epidemiology, and competition. Pharmacoeconomics 42, 117–131 (2024).

Article  PubMed  Google Scholar 

Michaeli, D. T. & Michaeli, T. Cancer drug prices in the United States: efficacy, innovation, clinical trial evidence, and epidemiology. Value Health 26, 1590–1600 (2023).

Article  PubMed  Google Scholar 

Rome, B. N., Egilman, A. C. & Kesseslheim, A. S. Trends in prescription drug launch prices. JAMA 327, 2145–2147 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Bennette, C. S., Richards, C., Sullivan, S. D. & Ramsey, S. D. Steady increase in prices for oral anticancer drugs after market launch suggest a lack of competitive pressure. Health Aff. 35, 805–812 (2016).

Article  Google Scholar 

Rind, D. et al. Unsupported prices increase report: unsupported price increases occurring in 2022. Institute for Clinical and Economic Review icer.org/wp-content/uploads/2023/04/UPI_2023_Report_121123.pdf (2023).

Jazowski, S. A., Wilson, L., Dusetzina, S. B., Zafar, S. Y. & Zullig, L. L. Association of high-deductible health plan enrollment with spending on and use of lenalidomide therapy among commercially insured patients with multiple myeloma. JAMA Netw. Open. 5, e2215720 (2022).

Article  PubMed  PubMed Central  Google Scholar 

McAuliff, M. Sky-high drug prices driven by pharma profits, House Dems charge. KFF Health News kffhealthnews.org/news/sky-high-drug-prices-driven-by-pharma-profits-house-dems-charge/ (2020).

Gordon, N., Stemmer, S. M., Greenberg, D. & Goldstein, D. A. Trajectories of injectable cancer drug costs after launch in the United States. J. Clin. Oncol. 36, 319–325 (2018).

Article  CAS  PubMed  Google Scholar 

Kesselheim, A. S., Avorn, J. & Sarpatwari, A. The high cost of prescription drugs in the United States: origins and prospects for reform. JAMA 316, 858–871 (2016).

Article  PubMed  Google Scholar 

Vokinger, K. N. & Naci, H. Negotiating drug prices in the US – lessons from Europe. JAMA Health Forum 3, e224801 (2022).

Article  PubMed  Google Scholar 

Mulcahy, A. W. et al. International Prescription Drug Price Comparisons (RAND, 2021).

Peter G. Peterson Foundation. How Much Does the United States Spend on Prescription Drugs Compared to Other Countries? (Peter G. Peterson Foundation, 2022).

IQVIA. Global Oncology Trends 2023 (IQVIA, 2023).

Vokinger, K. N. et al. Analysis of launch and postapproval cancer drug pricing, clinical benefit, and policy implications in the US and Europe. JAMA Oncol. 7, e212026 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Goldstein, A. House Democrats find in three-year investigation that drug prices are ‘unsustainable, unjustifiable and unfair.' Washington Post www.washingtonpost.com/health/2021/12/10/house-democrats-find-three-year-investigation-that-drug-prices-are-unsustainable-unjustifiable-unfair/ (2021).

Shmerling, R. H. Why Do Your Prescription Drugs Cost So Much? (Harvard Health Publishing, 2024).

PDQ® Adult Treatment Editorial Board. Financial Toxicity and Cancer Treatment (PDQ®) – Health Professional Version (National Cancer Institute, 2024).

Doshi, J. A., Li, P., Huo, H., Pettit, A. R. & Armstrong, K. A. Association of patient out-of-pocket costs with prescription abandonment and delay in fills of novel oral anticancer agents. J. Clin. Oncol. 36, 476–482 (2018).

Article  CAS  PubMed  Google Scholar 

Dusetzina, S. B. et al. Many Medicare beneficiaries do not fill high-price specialty drug prescriptions. Health Aff. 41, 487–496 (2022).

Article  Google Scholar 

Dusetzina, S. B., Winn, A. N., Abel, G. A., Huskamp, H. A. & Keating, N. L. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J. Clin. Oncol. 32, 306–311 (2014).

Article  PubMed  Google Scholar 

Park, J. & Look, K. A. Relationship between objective financial burden and the health-related quality of life and mental health of patients with cancer. J. Oncol. Pract. 14, e113–e121 (2018).

Article  PubMed  Google Scholar 

Altice, C. K., Banegas, M. P., Tucker-Seeley, R. D. & Yabroff, K. R. Financial hardships experienced by cancer survivors: a systematic review. J. Natl Cancer Inst. 109, dw205 (2016).

Article  Google Scholar 

Kent, E. E. et al. Are survivors who report cancer-related financial problems more likely to forgo or delay medical care? Cancer 119, 3710–3717 (2013).

Article  PubMed  Google Scholar 

Zafar, S. Y. et al. The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient’s experience. Oncologist 18, 381–390 (2013).

Article  PubMed  PubMed Central  Google Scholar 

Yeung, K., Barthold, D., Dusetzina, S. B. & Basu, A. Patient and plan spending after state specialty-drug out-of-pocket spending caps. N. Engl. J. Med. 383, 558–566 (2020).

Article  PubMed  Google Scholar 

Dusetzina, S. B., Jazowski, S., Cole, A. & Nguyen, J. Sending the wrong price signal: why do some brand-name drugs cost Medicare beneficiaries less than generics? Health Aff. 38, 1188–1194 (2019).

Article  Google Scholar 

Dusetzina, S. B., Huskamp, H. A., Winn, A. N., Basch, E. & Keating, N. L. Out-of-pocket and health care spending changes for patients using orally administered anticancer therapy after adoption of state parity laws. JAMA Oncol. 4, e173598 (2018).

Article  PubMed  Google Scholar 

Dusetzina, S. B. et al. Oral oncology parity laws, medication use, and out-of-pocket spending for patients with blood cancers. J. Natl Cancer Inst. 112, 1055–1062 (2020).

Article  PubMed  Google Scholar 

Spargo, A. et al. The effects of oral anticancer parity laws on out-of-pocket spending and adherence among commercially insured patients with chronic myeloid leukemia. J. Manag. Care Spec. Pharm. 27, 554–564 (2021).

PubMed  Google Scholar 

Chin, A. L., Bentley, J. P. & Pollom, E. L. The impact of state parity laws on copayments for and adherence to oral endocrine therapy for breast cancer. Cancer 125, 374–381 (2019).

Article  PubMed  Google Scholar 

Dusetzina, S. B. et al. Comparison of anticancer medication use and spending under US oncology parity laws with and without out-of-pocket spending caps. JAMA Health Forum 2, e210673 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Kirchner, S. M. et al. The parity paradigm: can legislation help reduce the cost burden of oral anticancer medications? Value Health 19, 88–99 (2016).

Article  Google Scholar 

Prasad, V., Jesus, K.De & Mailankody, S. The high price of anticancer drugs: origins, implications, barriers, solutions. Nat. Rev. Clin. Oncol. 14, 381–390 (2017).

Article  PubMed  Google Scholar 

Avorn, J. The $2.6 billion pill – methodologic and policy considerations. N. Engl. J. Med. 372, 1877–1879 (2015).

Article  CAS  PubMed  Google Scholar 

Butler, J. Drug Price Transparency Laws Position States to Impact Drug Prices (National Academy for State Health Policy, 2022).

National Academy for State Health Policy. What are we Learning From State Reporting on Drug Pricing? (National Academy for State Health Policy, 2019).

Clark, B. & Puthiyath M. S. Can State Prescription Drug Affordability Boards Address High-cost Drug Prices? (The Commonwealth Fund, 2022).

Becker, C. Digging into prescription drug data: affordability boards and transparency. National Conference of State Legislatures www.ncsl.org/health/digging-into-prescription-drug-data-affordability-boards-and-transparency (2022).

Holcombe, D. Prescription Drug Affordability Boards and Drug Importation – at or coming to a state near you? (Oncology Practice Management, 2024).

Feldman, M. A. Prescription Drug Affordability Boards: Another Quick Fix with Unintended Consequences? (MDedge, 2023).

Community Oncology Alliance. COA Position Statement on Prescription Drug Affordability Boards (Community Oncology Alliance, 2023).

Wingerter, M. Enbrel drugmaker sues over Colorado’s potential price cap, says prescription drug board is unconstitutional. The Denver Post www.denverpost.com/2024/03/26/amgen-sues-colorado-prescription-drug-affordability-board-enbrel-price-cap/#:~:Text=The%20lawsuit%2C%20filed%20in%20U.S.,be%20overturned%20by%20the%20courts (2024).

Gudiksen, K. L., Chang, S. M. & King, J. S. Navigating Legal Challenges to State Efforts to Control Drug Prices: Pharmacy Benefit Manager Regulation, Price Gouging, and Price Transparency (National Academy for State Health Policy, 2019).

Ryan, M. S. & Sood, N. Analysis of state-level drug pricing transparency laws in the United States. JAMA Netw. Open. 2, e1912104 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Baldwin, Braun lead bill to require transparency for skyrocketing drug prices. Tammy Baldwin: United States Senator for Wisconsin www.baldwin.senate.gov/news/press-releases/baldwin-braun-lead-bill-to-require-transparency-for-skyrocketing-drug-prices (2023).

Grassley, Cantwell introduce bipartisan bill to combat rising prescription drug prices and provide more transparency. Chuck Grassley www.grassley.senate.gov/news/news-releases/grassley-cantwell-introduce-bipartisan-bill-to-combat-rising-prescription-drug-prices-and-provide-more-transparency (2022).

Cubanski, J., Neuman, T. & Freed, M. Explaining the Prescription Drug Provisions in the Inflation Reduction Act (Kaiser Family Foundation, 2023).

Hernandez, I. et al. Price benchmarks of drugs selected for Medicare price negotiation and their therapeutic alternatives. J. Manag. Care Spec. Pharm. 30, 762–772 (2024).

PubMed  PubMed Central  Google Scholar 

Medicare Drug Price Negotiation Program. Fact sheet: key information on the process for the first round of negotiations for the Medicare Drug Price Negotiation Program. Centers for Medicare & Medicaid Services www.cms.gov/files/document/fact-sheet-negotiation-process-flow.pdf (2023).

Gardner, L. Drugmakers, trade groups push back against Medicare drug price negotiations. Politico www.politico.com/news/2023/08/29/drugmakers-trade-groups-push-back-against-medicare-drug-price-negotiations-00111936 (2023).

Baron, Z. & Twinamatsiko, A. A deep dive into takings clause challenges to the Medicare Drug Price Negotiation Program. Health Affairs www.healthaffairs.org/content/forefront/deep-dive-into-takings-clause-challenges-medicare-drug-price-negotiation-program (2023).

Ranganathan, S. & Baron, Z. Another administration win in Medicare drug price negotiation lawsuits. Health Affairs www.healthaffairs.org/content/forefront/another-administration-win-medicare-drug-price-negotiation-lawsuits (2024).

Briefing Room. Fact Sheet: Biden-Harris administration announces new, lower prices for first ten drugs selected for Medicare price negotiation to lower costs for millions of Americans. The White House